Apr
25
2019

Understanding RSV: Severe disease and the long term consequences

By OVG

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are inviting volunteers to take part in a study to help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children, and sometimes causes children to be so unwell they have to be admitted to hospital.

Some facts about RSV disease (respiratory syncytial virus):

Jul
09
2018

POInT

By OVG

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

Mar
12
2018

Be on the TEAM: Teenagers against Meningitis

By OVG

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom.  Teenagers at participating schools are being asked to take part by local research teams involved.

Aug
30
2017

Burden of RSV Disease

By OVG

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

  • it causes coughs, colds and chest infections
  • is responsible for around 1 in 6 hospital admissions for infants  in the UK
  • The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

Apr
28
2016

ImmunoglobuliN in the Treatment of Encephalitis

By OVG

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, OX3 7LE.

This unit receives National Institute for Health Research CTU Support Funding. This funding has been awarded to support the unit in developing and supporting NIHR trials.